Industry
Biotechnology
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Loading...
Open
1.41
Mkt cap
295M
Volume
3.4M
High
1.47
P/E Ratio
-2.77
52-wk high
4.32
Low
1.35
Div yield
N/A
52-wk low
1.19
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 12:18 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 12:16 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 9:16 pm
Portfolio Pulse from Benzinga Insights
August 12, 2024 | 6:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 5:42 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 10:43 am
Portfolio Pulse from Benzinga Insights
July 23, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 9:35 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.